Lilly begins trial for 2nd COVID-19 antibody therapy

By The Science Advisory Board staff writers

June 8, 2020 -- Eli Lilly and its partner Junshi Biosciences of Shanghai, China, have begun a phase I clinical trial for Eli Lilly's second COVID-19 antibody therapy.

JS016 is a recombinant, fully human monoclonal antibody that specifically binds to the SARS-CoV-2 spike protein receptor-binding domain. Lilly and Junshi Biosciences are developing it together in China; Lilly has exclusive rights to develop the therapy for the rest of the world and plans to begin a trial with patients in the U.S. soon, it said. Both companies will assess the safety, pharmacokinetics, and immunogenicity of JS016 in healthy participants who have not been diagnosed with COVID-19, according to Lilly.

JS016 is Lilly's second antibody treatment for COVID-19 to undergo clinical trials. The first, LY-CoV555, is in a phase I trial and is being tested in patients hospitalized for the disease.

Lilly begins COVID-19 antibody treatment clinical trials
Eli Lilly announced that the first patients have been dosed with its lead COVID-19 antibody treatment candidate, LY-CoV555, according to the firm. The...
AbCellera partners with Lilly for antibody discovery
AbCellera Biologics has joined forces with Eli Lilly on a multiyear initiative to identify antibodies for up to nine therapeutic targets.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter